I am a healthcare professional

Notice

Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.

Cookies

We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site

Roche and Genentech at

SABCS 2023

December 05 - December 09

San Antonio, USA

sabcs.org

Medical Materials

Agenda

Coming soon

03:30 PM

Duration 15mins Hall 1

Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial

Ignatiadis M et al.

Oncology | Breast Cancer

06:00 PM

Duration 120mins San Antonio, USA

Circulating tumor DNA dynamics in acelERA Breast Cancer: a Phase II study of giredestrant for estrogen receptor-positive, HER2-negative, previously treated advanced breast cancer

Collier A, Bardia A, Sohn J, Lim E, Chavez-MacGregor M, Martin M, Martinalbo J, Pérez-Moreno P.D, Moore H

Oncology | Breast Cancer

11:00 PM

Duration 120mins San Antonio, USA

Risk of anaphylaxis associated with the use of pertuzumab or other biologics with potential for use outside the hospital

Sanglier T, Chambers T, Harton J, Wahyudi L.A, Genevray M, Restuccia E, Droz-Perroteau C, Dang C.T

Oncology | Breast Cancer

Duration 120mins San Antonio, USA

INAVO122: a Phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients with PIK3CA-mutated, HER2-positive advanced breast cancer

Swain S.M, Barrios C.H, Basho R, Curigliano G, Harbeck N, Huang C-S, Loi S, Turner N.C, Chen J, Henschel V, Warburton S, Amair-Pinedo F, Cortés J

Oncology | Breast Cancer

Duration 120mins San Antonio, USA

INAVO121: Phase III study of inavolisib + fulvestrant vs alpelisib + fulvestrant in patients with hormone receptor-positive, HER2-negative, PIK3CA mutated locally advanced or metastatic breast cancer

Juric D, Kalinsky K.M, Im S-A, Ciruelos E, Bianchini G, Barrios C.H, Jacot W, Schmid P, Loi S, Rugo H.S, Craine V, Huchinson K.E, Flechais A, Thanopoulou E, Harbeck N

Oncology | Breast Cancer

01:00 PM

Duration 60mins San Antonio, USA

Brain metastases in metastatic breast cancer: prevalence per line of treatment and cumulative incidence in a cohort of 18075 real-world patients

Sammons S.L, Leone J.P, Sanglier T, Lambert P, Montemurro F, Poppe R, Restuccia E, Tolaney SM, Lin NU

Oncology | Breast Cancer

Duration 60mins San Antonio, USA

MORPHEUS Hormone Receptor-Positive Breast Cancer: interim analysis of a Phase Ib/II study of fulvestrant ± atezolizumab and abemaciclib triplet treatment in patients with metastatic disease

Jung KH, Im S-A, Yardley D, Hurvitz SA, Lee KS, Sonnenblick A, Shachar S, Tan AR, Comen E, Gal-Yam E, Brufsky AM, Rugo HS, Zhu J, Bader E, DuPree K, Cahuzac C, Young F, Schwab R, Cha E, Telli ML

Oncology | Breast Cancer

06:00 PM

Duration 120mins San Antonio, USA

ASTEFANIA: a Phase III study of ado-trastuzumab emtansine plus atezolizumab or placebo as adjuvant therapy in patients with residual invasive breast cancer after neoadjuvant HER2-targeted therapy and chemotherapy

Schmid P, Bachelot T, Bianchini G, Harbeck N, Loi S, Park Y.H, Prat A, Gilham L, Boulet T, Gochitashvili N, Monturus E, Lambertini C, Nyawira B, Knott A, Hurvitz S.A

Oncology | Breast Cancer

11:00 PM

Duration 120mins San Antonio, USA

Exposure–response analyses of GO39932: a Phase Ia/b study of giredestrant in estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

Jhaveri K, Lien YT, Turner N.C, Lim E, Cannon M, Anziano R, Langenhorst J, Yoshida K, Malhi V, Gates M.R, Eng-Wong J, Li C, Shah M.D, Pérez-Moreno P.D, Yu J, Bardia A

Oncology | Breast Cancer

01:00 PM

Duration 60mins San Antonio, USA

Interim analysis of giredestrant + inavolisib in MORPHEUS Breast Cancer: a Phase Ib/II study of giredestrant treatment combinations in estrogen receptor-positive, HER2-negative, locally advanced/metastatic breast cancer

Rugo H.S, Gion Cortès M, Hernando C, Jung K.H, Oliveria M, Telli M.L, Vidal G, Vatandoust S, Zhu J, Schwab R, Ngo H.X, Ferreira E, Collier A, Cahuzac C, Gal-Yam E

Oncology | Breast Cancer

Duration 60mins San Antonio, USA

Key drivers of therapeutic response and resistance to giredestrant from GO39932: a Phase Ia/b study in patients with estrogen receptor-positive, HER2 negative, locally advanced or metastatic breast cancer

Liang J, Ong C, Giltnane J.M, Aimi J, Chang C-W, Gates M.R, Eng-Wong J, Pérez-Moreno P.D, Jhaveri K.L, Lim E, Turner N.C, Moore H.M

Oncology | Breast Cancer

05:00 PM

Duration 180mins Hall 1

Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis

Loibl S, Mano MS, Untch M, Huang C-S, Mamounas EP, Wolmark N, Knott A, Siddiqui A, Boulet T, Nyawira B, Restuccia E, Geyer Jr CE

Oncology | Breast Cancer

05:15 PM

Duration 180mins Hall 1

Inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III INAVO120 primary analysis

Komal L. Jhaveri

Oncology | Breast Cancer